What is XERS's market cap?

$1.91B, based on the Nov 4 close of $10.46.

Does Xeris Biopharma Holdings pay a dividend?

No regular cash dividend has been paid in the last year.

How much of XERS is sold short?

8.0M shares, 4.6% of float, as of Oct 15, 2026.

What sector is XERS in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · XERSHealthcarePharmaceuticals

Xeris Biopharma Holdings, Inc. Common Stock (XERS)

$10.46+1.06%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$10.46▲ 5.66% in range

Nov 4, 2025Low $5.29 · High $11.13Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Xeris Biopharma Holdings closed at $10.46 on Nov 4, up 1.06%, 6.0% below its 52-week closing high. Volume of 3.2M shares was 1.44× its 20-day average (above normal).

Split-adjusted performance: +3.9% over one month, +64.2% over six months, +5.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $92.10M, up 28.7% from a year earlier, with a net margin of -33.8%.

Short interest was 8.0M shares at the Oct 15 settlement, up 11.5% from the prior report (4.6% of float, 3.3 days to cover).

Market cap$1.91B182.3M shares

Revenue · quarter$92.1M+28.7% YoY

Diluted EPS$-0.18—

P/E · TTM—P/S 5.7×

Net margin-33.8%Gross 86.4%

Dividend yieldNone

52-week range5.29 – 11.13−6.0% from high

Volume3.2M1.44× 20-day avg

Volatility · 60d51.6%Annualised

Short % of float4.6%3.3 days to cover

Net cash-$130.8MCash $121.7M

Next earnings—Not scheduled

Split-adjusted performance

1W −1.7%1M +3.9%3M +42.1%6M +64.2%YTD +33.2%1Y +5.7%3Y +526.3%5Y +471.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum95

Revenue growth70

Net margin50

Value (low P/E)—

Size80

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short8.0M+11.5% vs prior

Days to cover3.3Settled Oct 15

% of float4.6%

Short vol. 10d33.8%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
XERSXeris Biopharma Holdings	$10.46	+1.06%	+64.2%	+28.7%	−33.8%	—	$1.91B
AGIOAgios Pharmaceuticals	$31.38	+0.58%	+16.3%	+259.3%	−225.1%	—	$1.87B	Compare
ZBIOZenas BioPharma	$28.46	+0.28%	+36.6%	—	−11145.6%	—	$1.85B	Compare
SLSSELLAS Life Sciences Group	$9.14	+3.04%	+77.5%	—	—	—	$1.85B	Compare
TRVITrevi Therapeutics	$13.99	+0.90%	−1.9%	—	—	—	$1.99B	Compare
GENBGenerate Biomedicines	$14.16	+2.24%	—	—	−1065.2%	—	$1.82B	Compare
HRMYHarmony Biosciences Holdings	$34.42	−7.04%	+5.0%	+30.3%	28.9%	11.1	$2.00B	Compare
SRPTSarepta Therapeutics,	$18.99	+2.43%	−17.5%	−34.3%	−1.2%	—	$2.01B	Compare
BRVEBraveheart Bio	$20.11	−6.01%	—	—	—	—	$1.81B	Compare

News about Xeris Biopharma Holdings

All news →

No recent articles focused on Xeris Biopharma Holdings.

Quick answers

What does Xeris Biopharma Holdings do?: Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
What is XERS's market cap?: $1.91B, based on the Nov 4 close of $10.46.
Does Xeris Biopharma Holdings pay a dividend?: No regular cash dividend has been paid in the last year.
How much of XERS is sold short?: 8.0M shares, 4.6% of float, as of Oct 15, 2026.
What sector is XERS in?: Healthcare, in the Pharmaceuticals industry.

About Xeris Biopharma Holdings

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

HQ: Chicago, IL435 employeesListed Jun 21, 2018xerispharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology